Application:

  • Human aging is a major driver of chronic diseases, including fatty liver disease, neurodegeneration, cardiac dysfunction, and metabolic disorders
  • Animal models poorly predict human aging due to species-specific differences in metabolism, genetics, and lifespan
  • Human aging unfolds over decades, making it difficult to track dynamic aging processes or validate therapeutic interventions
  • High clinical attrition rates highlight the need for predictive, human-relevant aging platforms

Our innovation: 

  • Accelerated Microphysiological Aging (AMPSA) platform that induces key biological and functional features of elderly human tissues within ~70 days
  • Human liver, heart, and brain organoids aged in vitro by mimicking the endocrine and metabolic environment of old age
  • Sensor-embedded organoids enable continuous, real-time monitoring of metabolic and functional changes during aging
  • Robotic organoid handling allows standardized, high-throughput production and screening of thousands of organoids
  • Platform supports genetic perturbation studies, linking aging-related genes to functional tissue-level outcomes

Advantages: 

  • Human-relevant aging biology, overcoming key limitations of rodent models
  • Time-compressed aging, transforming decades-long processes into weeks
  • Longitudinal, real-time metabolic readouts, rather than static endpoint assays
  • Multi-organ capability, enabling parallel assessment of liver, heart, and brain aging
  • Scalable and high-throughput, suitable for drug discovery and genetic screening
  • Demonstrated induction of hallmarks of aging, including:
  • Mitochondrial dysfunction
  • Insulin resistance
  • Cellular senescence
  • Fibrosis, steatosis, and neurodegeneration-associated phenotypes

Opportunity:

We are seeking collaboration with pharmaceutical, biotech, and technology companies developing therapies, discovery platforms, or tools for aging and age-related diseases, to:

  • Evaluate therapeutic candidates in aged human tissues
  • Identify and validate aging biomarkers
  • Discover genetic and metabolic drivers of human aging
  • Reduce reliance on animal models in aging research

Contact in Yissum: Ariela Markel